Illumina sees FY19 adjusted EPS $6.50-$6.60, consensus $6.37

Sees FY19 revenue $3.76B-$3.8B, $3.81B. While presenting last night at the JPMorgan Healthcare Conference, Illumina President & CEO Francis deSouza said, according to a transcript: “Looking to 2019, we’re expecting revenue growth in the range of 13% to 14%. We expect our sequencing business to grow in the mid teens with sequencing consumables expected to grow above 20% reflecting the strength of our product portfolio and expanding market opportunities. We’re forecasting low single digit growth in our arrays business in 2019. Our outlook reflects a cautious view of the consumer opportunity as we start the year. Although we expect this business to re accelerate, as consumer health and international opportunities ramp up. Overall, we expect 2019 revenue of between $3.76B-$3.8B, representing an increase of approximately $450 million at the midpoint. Following record system revenue in the fourth quarter, and reflecting expected seasonality, we expect total revenue to be more back end loaded in 2019 than it was in 2018. We expect GAAP EPS in the range of $6.07 and $6.17 and non-GAAP EPS in the range of $6.50 and $6.60. This excludes the expected impact of our acquisition of Pacific Biosciences, which we continue to expect to close in the middle of the year.”
https://thefly.com/landingPageNews.php?id=2845547